Truist Securities Downgrades Pacira BioSciences to Hold, Raises Price Target to $36.5

Benzinga Newsdesk www.benzinga.com Negative 58.4%

Neg 58.4% Neu 0% Pos 0%

Truist Securities analyst Anish Nikhanj downgrades Pacira BioSciences (NASDAQ:PCRX) from Buy to Hold and raises the price target from $31 to $36.5.